Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report 2026

Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Overview

• Fibrodysplasia Ossificans Progressiva (FOP) Treatment market size has reached to $0.5 billion in 2025 • Expected to grow to $0.76 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rise In Gene Therapy Adoption Driving Growth Of The Market Due To Advancements In Genetic Research And Regulatory Support • Market Trend: Advancements In Targeted Therapies For Rare Genetic Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market?

Fibrodysplasia ossificans progressiva treatment refers to medical interventions aimed at managing the rare genetic condition where soft tissues progressively turn into bone, involving medications, surgery, or gene therapy to control symptoms and slow disease progression. These treatments focus on reducing inflammation, preventing further bone formation, and improving the quality of life for affected individuals. The main drug class of fibrodysplasia ossificans progressiva (FOP) treatment is corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, and others. Corticosteroids are specifically effective in reducing inflammation and modulating the immune response in various conditions. Treatment options for FOP encompass medication, surgery, and occupational therapy. These treatments can be administered via oral, topical, or parenteral routes and are used in hospitals, research institutes, and specialty clinics.

What Is The Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Growth Forecast?

The fibrodysplasia ossificans progressiva (fop) treatment market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in gene therapy drugs, increased orphan drug approvals, rising investment in rare disease research, improved diagnostic accuracy, expansion of personalized medicine. Major trends in the forecast period include rising focus on anti-inflammatory drug therapies, increased research in gene and molecular therapies, growing emphasis on early diagnosis and disease monitoring, expansion of rare disease clinical trials, improved multidisciplinary care approaches.

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Segmentation

1) By Drug Class: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Bisphosphonates, Other Drug Classes 2) By Treatment: Surgery, Medication, Occupational Therapy 3) By Route Of Administration: Oral, Topical, Parenteral 4) By End-User: Hospitals, Research Institutes, Specialty Clinics Subsegments: 1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone 2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Celecoxib 3) By Bisphosphonates: Alendronate, Risedronate, Zoledronic Acid 4) By Other Drug Classes: Monoclonal Antibodies, Immunosuppressants, Gene Therapy Drugs

What Is The Driver Of The Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market?

The increasing adoption of gene therapy is expected to fuel the growth of the fibrodysplasia ossificans progressiva (FOP) treatment market going forward. Gene therapy is a medical treatment that involves altering or replacing genes within a person's cells to treat or prevent disease. The increasing adoption of gene therapy is driven by advancements in genetic research, improved treatment outcomes for previously untreatable conditions, and growing regulatory support for innovative therapies. Gene therapy for fibrodysplasia ossificans progressiva involves targeting and correcting mutations in the ACVR1 gene to prevent abnormal bone formation. For instance, in March 2024, according to the Bright Cell Healthcare Institute, a Vietnam-based regenerative-medicine organization offering clinical-grade stem-cell therapies, there are currently 36 FDA-approved gene therapies, with approximately 500 candidates in development, positioning the sector for accelerated expansion as 10–20 new approvals per year are projected by 2025. Therefore, the increasing adoption of gene therapy is driving the growth of the fibrodysplasia ossificans progressiva (FOP) treatment industry.

Key Players In The Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market

Major companies operating in the fibrodysplasia ossificans progressiva (fop) treatment market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., UCB S.A., Incyte Corporation, Ipsen Pharma, Alnylam Pharmaceuticals Inc., Blueprint Medicines Corporation, Ashibio, Ultragenyx Pharmaceutical Inc., Scholar Rock Holding Corporation, PTC Therapeutics Inc., Keros Therapeutics Inc., Biogen Inc.

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Trends and Insights

Major companies operating in the fibrodysplasia ossificans progressiva (FOP) treatment market are focusing on developing advanced drugs such as retinoid-induced capsules to address the unmet medical needs of patients by targeting the underlying genetic mutations associated with the condition, thereby improving treatment outcomes and quality of life. Retinoids are vitamin A derivatives used in medical treatments to regulate cell growth and support immune responses, particularly for skin and certain cancer therapies. For instance, in August 2023, Ipsen, a France-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its sohonos capsules. It is a retinoid-indicated medication for fibrodysplasia ossificans progressiva (FOP), aimed at reducing new abnormal bone growth (heterotopic ossification). It provides a vital treatment option for both adult and pediatric patients, helping to improve mobility and overall quality of life.

What Are Latest Mergers And Acquisitions In The Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market?

In March 2024, the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), a US-based non-profit organization, partnered with Wazoku Crowd to enhance research efforts, support affected families, and advance the search for a cure for fibrodysplasia ossificans progressiva. Wazoku Crowd is a UK-based innovation and crowdsourcing company that provides a platform for organizations to crowdsource ideas, solutions, and innovations.

Regional Outlook

North America was the largest region in the fibrodysplasia ossificans progressiva (FOP) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market?

The fibrodysplasia ossificans progressiva (FOP) treatment market consists of revenues earned by entities by providing services such as supportive therapies, physical therapy, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibrodysplasia ossificans progressiva (FOP) treatment market also includes sales of bone morphogenetic protein (BMP) inhibitors, anti-inflammatory drugs, pain relievers, muscle relaxants, pain relievers, and muscle relaxants care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report 2026?

The fibrodysplasia ossificans progressiva (fop) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fibrodysplasia ossificans progressiva (fop) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.